Inflammasomes in Cardiovascular Diseases: Current Knowledge and Future Perspectives.

Area of Science:

• Cardiovascular Research
• Immunology
• Inflammation Biology

Background:

• Chronic inflammation is a key factor in cardiovascular disorders.
• Inflammasomes, particularly NOD-like receptor protein 3 (NLRP3), are critical mediators.
• NLRP3 activation by danger signals drives atherosclerosis, heart failure, and pericarditis.

Purpose of the Study:

• To explore the role of inflammasomes in cardiovascular disease pathogenesis.
• To review current and emerging therapeutic strategies targeting inflammasome pathways.
• To highlight the potential for improved cardiovascular patient management.

Main Methods:

• Literature review of inflammasome involvement in cardiovascular conditions.
• Analysis of therapeutic agents targeting inflammasome activation or downstream pathways.
• Synthesis of findings on existing and novel anti-inflammasome compounds.

Main Results:

• NLRP3 inflammasome activation contributes to atherosclerosis, heart failure, and pericarditis.
• Approved therapies like colchicine, IL-1 inhibitors, and SGLT2 inhibitors show cardiovascular benefits.
• Novel NLRP3 inhibitors like MCC950 are under investigation.

Conclusions:

• Inflammasomes are significant contributors to cardiovascular disease progression.
• Targeting inflammasome pathways presents a promising therapeutic avenue.
• Further research is essential to validate novel treatments for cardiovascular inflammation.